CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial

Pierre‐François Laterre, Bruno François, Thierry Dugernier et al.|The Lancet Infectious Diseases|2019

Cited by 59